

## Henry Schein Reports Fourth Quarter Diluted EPS from Continuing Operations of \$0.59

February 22, 2006

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 22, 2006--Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported financial results for the quarter ended December 31, 2005.

Net sales for the fourth quarter of 2005 were \$1.34 billion, an increase of 16.2% from the fourth quarter of 2004 (See Exhibit A for details of sales growth). This increase includes 18.4% local currency growth (13.5% internally generated and 4.9% from acquisitions) offset by a 2.2% decline related to foreign currency exchange. The fourth quarter of 2005 included an additional week compared with the fourth quarter of 2004. The Company estimates that the extra week accounted for approximately 5% to 6% of net sales growth.

Fourth quarter income from continuing operations was \$52.5 million, up 78.4% compared with the fourth quarter of 2004, and earnings per diluted share from continuing operations were \$0.59, up 78.8% compared with the prior-year quarter. Excluding a one-time charge in the fourth quarter of 2004 of \$8.4 million after tax, fourth quarter 2005 income and earnings per diluted share from continuing operations grew by 38.9% and 37.2% respectively (See Exhibit B for details).

"Our excellent fourth quarter results cap off a year of solid financial performance by Henry Schein. We are pleased to report record quarterly net sales that reflect market share gains in our Dental, Medical and International businesses, which were further bolstered by strategic acquisitions," commented Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.

For the quarter, Dental sales increased 17.4%, including 17.1% growth in local currencies (12.2% internally generated and 4.9% from acquisitions) and 0.3% related to foreign currency exchange. Of the 17.1% local currency growth, Dental consumable merchandise sales increased 15.9% (11.0% internal growth and 4.9% acquisition growth) and Dental equipment sales and service revenues were up 20.0% (15.0% internal growth and 5.0% acquisition growth). Internal sales growth in Dental consumable merchandise and in equipment sales and service revenues was augmented by the acquisitions of Ash Temple in Canada and Barton-Cyker in the United States.

Medical sales increased 20.8% during the fourth quarter (19.6% internal growth and 1.2% acquisition growth), reflecting an acceleration of growth from recent quarters. Medical sales other than influenza vaccine sales increased 13.2% (11.9% internal growth and 1.3% acquisition growth). Medical sales for the 2005 fourth quarter reflect the resumption of distribution of Chiron's Fluvirin(R) influenza vaccine. The Company sold 3.7 million doses of Fluvirin during the quarter, which was at the high end of its estimate of 2 million to 4 million doses.

For the quarter, International sales increased 10.3%, including 18.5% growth in local currencies (9.3% internally generated and 9.2% from acquisitions) offset by a 8.2% decline related to foreign currency exchange. Internal sales growth was bolstered by the acquisitions of the Demedis operations in Austria, Halas Dental in Australia and Shalfoon Bros. in New Zealand.

Technology and Value-Added Services sales were 4.7% ahead of prior year, including 4.5% growth in local currencies (all internal) and 0.2% related to foreign currency exchange. Electronic services revenues continued a strong double-digit growth trend.

On November 3, 2005, Henry Schein celebrated its 10-year anniversary as a publicly traded company. Commenting on this milestone, Mr. Bergman said, "Among our reasons for pursuing an initial public offering was to provide funding for future growth, and as measured by any number of metrics, our growth during the past decade has been impressive. To cite just a couple of examples of our financial performance, since 1995 our net sales have grown at a compound annual growth rate of slightly more than 22%, rising seven-fold from \$616 million in 1995 to \$4.6 billion in 2005.

"The 10-year income from continuing operations compound annual growth rate was even higher, at 33%," he continued. "Income from continuing operations during this period rose 18-fold, from \$9 million in 1995 to \$162 million in 2005. And our earnings per diluted share, which stood at a split-adjusted \$0.35 in 1995, reached \$1.82 per share in 2005 as we reported today, representing a 10-year compound annual growth rate of 18%."

The Company noted that all 1995 financial data does not reflect subsequent restatements for pooling of interest transactions and excludes certain proforma adjustments.

### Stock Repurchase Plan

In June 2004 and again in November 2005 the Company announced share repurchase programs of up to \$100 million worth of common stock each, under which 632,000 shares were repurchased during the fourth quarter at an average price of \$39.81 per share. The impact of the repurchase of shares under this program on fourth quarter diluted EPS was immaterial.

### 2006 EPS Guidance

Henry Schein affirms 2006 financial guidance, as first announced on November 28, 2005, as follows:

- 2006 diluted EPS is expected to be \$2.20 to \$2.26, excluding the impact of expensing stock options per Financial Accounting Standards No. 123(R), which the Company estimates to be \$0.12 per diluted share.
- Diluted EPS growth is expected to be in the low double digits percentage range for the first half of 2006, and then to accelerate for the second half of the year due to the impact of seasonal influenza vaccine sales and the timing of certain expenses.
- This 2006 diluted EPS guidance includes Henry Schein's expectations that it will distribute approximately 15 million to 17 million doses of influenza vaccine during 2006, including product manufactured by GlaxoSmithKline Biologicals (which

includes the former ID Biomedical), Chiron Corporation and sanofi pasteur.

- All guidance is for current continuing operations including completed acquisitions, and does not include the impact of potential future acquisitions.

#### Fourth Quarter Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at [www.henryschein.com](http://www.henryschein.com). In addition, a replay will be available beginning shortly after the call has ended.

#### About Henry Schein

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 475,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions. The Company's sales reached a record \$4.6 billion in 2005. The Company operates through a centralized and automated distribution network, which provides customers in more than 125 countries with a comprehensive selection of more than 160,000 national and Henry Schein private-brand products.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as Aruba(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices - DENTRIX(R) and Easy Dental(R) for dental practices, and AVImark(R) for veterinary clinics.

Headquartered in Melville, N.Y., Henry Schein employs nearly 11,000 people and has operations in 19 countries. For more information, visit the Henry Schein Web site at [www.henryschein.com](http://www.henryschein.com).

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of the Company's operations and financial condition, including factors that may affect its business and future prospects, is contained in documents the Company has filed with the SEC and will be contained in all subsequent periodic filings made with the SEC. These documents identify in detail important risk factors that could cause the Company's actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect the Company; financial risks associated with the Company's international operations; fluctuations in quarterly earnings; transitional challenges associated with acquisitions; regulatory and litigation risks; the dependence on the Company's continued product development, technical support and successful marketing in the technology segment; the Company's dependence upon sales personnel and key customers; the Company's dependence on its senior management; the Company's dependence on third parties for the manufacture and supply of its products; possible increases in the cost of shipping the Company's products or other service trouble with the Company's third-party shippers; risks from rapid technological change; and risks from potential increases in variable interest rates.

The order in which these factors appear should not be construed to indicate their relative importance or priority. The Company cautions that these factors may not be exhaustive and that many of these factors are beyond the Company's ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. The Company undertakes no duty and has no obligation to update forward-looking statements.

HENRY SCHEIN, INC.  
CONSOLIDATED STATEMENTS OF INCOME  
(in thousands, except per share data)

	Three Months Ended		Years Ended	
	December 31, 2005	December 25, 2004	December 31, 2005	December 25, 2004
	(unaudited)	(unaudited)		
Net sales	\$1,343,141	\$1,156,122	\$4,635,929	\$3,898,485
Cost of sales	965,666	841,792	3,318,993	2,844,020
Gross profit	377,475	314,330	1,316,936	1,054,465
Operating expenses:				
Selling, general and administrative	288,240	264,085	1,035,848	844,715

Operating income	89,235	50,245	281,088	209,750
Other income (expense):				
Interest income	2,846	1,143	7,315	6,110
Interest expense	(7,222)	(5,582)	(25,508)	(17,596)
Other, net	744	(83)	1,659	365
	-----	-----	-----	-----
Income from continuing operations before taxes, minority interest and equity in earnings of affiliates	85,603	45,723	264,554	198,629
Income taxes	(31,247)	(16,913)	(97,002)	(73,506)
Minority interest in net loss (income) of subsidiaries	(2,215)	221	(5,991)	(1,486)
Equity in earnings of affiliates	313	368	827	1,699
	-----	-----	-----	-----
Income from continuing operations	52,454	29,399	162,388	125,336
Discontinued operations:				
Income (loss) from operations of discontinued components	(1,268)	176	(18,448) (1)	4,745
Income tax benefit (expense)	514	(25)	7,386	(1,898)
	-----	-----	-----	-----
Income (loss) from discontinued operations	(754)	151	(11,062)	2,847
	-----	-----	-----	-----
Net income	\$51,700	\$29,550	\$151,326	\$128,183
	=====	=====	=====	=====
Earnings from continuing operations per share:				
Basic	\$0.60	\$0.34	\$1.87	\$1.44
	=====	=====	=====	=====
Diluted	\$0.59	\$0.33	\$1.82	\$1.40
	=====	=====	=====	=====
Earnings (loss) from discontinued operations per share:				

Basic	\$ (0.01)	\$ 0.00	\$ (0.13)	\$ 0.03
	=====	=====	=====	=====
Diluted	\$ (0.01)	\$ 0.00	\$ (0.12)	\$ 0.03
	=====	=====	=====	=====
Earnings per share:				
Basic	\$ 0.59	\$ 0.34	\$ 1.74	\$ 1.47
	=====	=====	=====	=====
Diluted	\$ 0.58	\$ 0.33	\$ 1.70	\$ 1.43
	=====	=====	=====	=====
Weighted-average common shares outstanding:				
Basic	87,075	86,595	87,006	87,253
	=====	=====	=====	=====
Diluted	89,261	88,546	89,187	89,462
	=====	=====	=====	=====

Note: The above prior period amounts have been adjusted to reflect the effects of our discontinued operations.

(1) Includes write-down of long-lived assets of \$11.9 million recorded in the third quarter of 2005.

HENRY SCHEIN, INC.  
CONSOLIDATED BALANCE SHEETS  
(in thousands, except share and per share data)

	December 31, 2005	December 25, 2004
	-----	-----
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 254,498	\$ 186,621
Available-for-sale securities	80,195	-
Accounts receivable, net of reserves of \$52,308 and \$44,852	582,617	554,666
Inventories	505,542	486,494
Deferred income taxes	35,505	28,795
Prepaid expenses and other	126,052	174,167
	-----	-----
Total current assets	1,584,409	1,430,743
Property and equipment, net	190,746	176,103
Goodwill	626,869	627,215
Other intangibles, net	123,204	129,285
Investments and other	57,892	70,324
	-----	-----
Total assets	\$ 2,583,120	\$ 2,433,670
	=====	=====

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Accounts payable	\$ 371,392	\$ 367,213
Bank credit lines	2,093	5,969
Current maturities of long-term debt	33,013	3,906
Accrued expenses:		
Payroll and related	96,113	89,431
Taxes	65,070	70,970
Other	156,433	156,410
	-----	-----
Total current liabilities	724,114	693,899
Long-term debt	489,520	525,682

Deferred income taxes	74,042	66,599
Other liabilities	53,547	28,999
Minority interest	12,353	12,438
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding	-	-
Common stock, \$.01 par value, 240,000,000 shares authorized, 87,092,238 outstanding on December 31, 2005 and 120,000,000 shares authorized, 86,650,428 outstanding on December 25, 2004	871	867
Additional paid-in capital	472,960	445,573
Retained earnings	735,079	615,265
Accumulated other comprehensive income	21,059	44,785
Deferred compensation	(425)	(437)
	-----	-----
Total stockholders' equity	1,229,544	1,106,053
	-----	-----
Total liabilities and stockholders' equity	\$ 2,583,120	\$ 2,433,670
	=====	=====

Note: Included above, as of December 31, 2005, there are approximately \$44 million of accounts receivable, net of reserves, and approximately \$16 million of inventories, net of reserves, related to discontinued operations.

HENRY SCHEIN, INC.  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
For the Periods Ended December 31, 2005 and December 25, 2004  
(in thousands)

	Three Months Ended		Years Ended	
	2005	2004	2005	2004
	-----		-----	
	(unaudited)	(unaudited)		
Cash flows from operating activities:				
Net income	\$ 51,700	\$ 29,550	\$ 151,326	\$ 128,183
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	17,798	18,095	60,345	51,326
Impairment from write-down of long-lived assets	-	-	11,928	-
Provision for losses on trade and other accounts receivable	889	2,031	6,524	3,820
Deferred income taxes	1,609	10,095	2,792	13,294

Stock issued to 401(k) plan	-	-	3,223	2,805
Undistributed earnings of affiliates	(313)	(368)	(827)	(1,699)
Minority interest in net income (loss) of subsidiaries	2,215	(221)	5,991	1,486
Other	(1,299)	(2,514)	(231)	1,519
Changes in operating assets and liabilities, net of acquisitions:				
Accounts receivable	27,643	(2,023)	(14,002)	(35,075)
Inventories	(27,641)	(18,338)	6,484	(28,614)
Other current assets	(11,505)	(18,406)	30,147	(13,919)
Accounts payable and accrued expenses	90,463	114,629	1,441	67,873
Net cash provided by operating activities	151,559	132,530	265,141	190,999
Cash flows from investing activities:				
Purchases of fixed assets	(14,625)	(13,150)	(50,829)	(37,837)
Payments for business acquisitions, net of cash acquired	(9,665)	19,654 (1)	(68,213)	(132,375)
Payments related to pending business acquisitions	-	(3,950)	-	(17,439)
Purchases of available-for-sale securities	(103,520)	-	(111,945)	-
Proceeds from sales of marketable securities	31,749	-	31,749	14,472
Proceeds from settlement of note receivable	2,616	-	14,395	-
Net proceeds from (payments for) foreign exchange forward contract settlements	7,188	(5,013)	30,818	(8,234)
Other	(9,414)	10,717	(8,841)	9,584
Net cash provided by (used in) investing activities	(95,671)	8,258	(162,866)	(171,829)

Cash flows from financing activities:				
Proceeds from issuance of long-term debt	-	-	-	240,000
Payments for debt issuance costs	-	(627)	(650)	(5,781)
Net payments for bank borrowings	(637)	(1,258)	(3,525)	(7,339)
Repayments of debt assumed in business acquisitions	-	-	-	(135,718)
Principal payments for long-term debt	(3,005)	(295)	(8,483)	(3,359)
Proceeds from issuance of stock upon exercise of stock options	4,222	2,172	29,500	21,425
Payments for repurchases of common stock	(25,159)	(11,547)	(52,276)	(82,213)
Other	182	144	(3,432)	(645)
	-----	-----	-----	-----
Net cash provided by (used in) financing activities	(24,397)	(11,411)	(38,866)	26,370
	-----	-----	-----	-----
Net change in cash and cash equivalents	31,491	129,377	63,409	45,540
Effect of exchange rate changes on cash and cash equivalents	2,930	(15,727)	4,468	(16,270)
Cash and cash equivalents, beginning of period	220,077	72,971	186,621	157,351
	-----	-----	-----	-----
Cash and cash equivalents, end of period	\$ 254,498	\$ 186,621	\$ 254,498	\$ 186,621
	=====	=====	=====	=====

NOTE: Certain prior period amounts have been reclassified to conform with the current period presentation.

(1) Primarily reflects proceeds received from the divestiture of DentalMV GmbH in July 2004 which was treated as a reduction of purchase price of the Demedis Group acquired in June 2004.

Exhibit A

Henry Schein, Inc.  
2005 Fourth Quarter and Full Year  
Sales Growth Rate Summary  
(unaudited)

Q4 2005 over Q4 2004  
-----

	Consolidated	Dental	Medical	International	Technology
Internal	13.5%	12.2%	19.6%	9.3%	4.5%
Acquisitions	4.9%	4.9%	1.2%	9.2%	-
Local Currency Sales Growth	18.4%	17.1%	20.8%	18.5%	4.5%
Foreign Currency Exchange	-2.2%	0.3%	-	-8.2%	0.2%
Total Sales Growth	16.2%	17.4%	20.8%	10.3%	4.7%

Full Year 2005 over Full Year 2004

	Consolidated	Dental	Medical	International	Technology
Internal	8.4%	11.3%	7.6%	4.8%	5.4%
Acquisitions	10.4%	6.6%	1.0%	30.9%	-
Local Currency Sales Growth	18.8%	17.9%	8.6%	35.7%	5.4%
Foreign Currency Exchange	0.1%	0.5%	-	-0.3%	0.2%
Total Sales Growth	18.9%	18.4%	8.6%	35.4%	5.6%

Exhibit B

Henry Schein, Inc.  
2005 Fourth Quarter and Full Year  
Details of Growth Comparison  
Income Statement Summary  
(in thousands, except per share data)  
(unaudited)

	Fourth Quarter		%	Full Year		%
	2005	2004	Growth	2005	2004	Growth
As Reported						
Net Sales	\$1,343,141	\$1,156,122	16.2%	\$4,635,929	\$3,898,485	18.9%
Operating Income	\$89,235	\$50,245	77.6%	\$281,088	\$209,750	34.0%
Margin	6.6%	4.3%	230 bp	6.1%	5.4%	68 bp
Income from Continuing Operations	\$52,454	\$29,399	78.4%	\$162,388	\$125,336	29.6%
Diluted EPS						



from Continuing Operations	\$0.59	\$0.33	78.8%	\$1.82	\$1.40	30.0%
Net Income	\$51,700	\$29,550	75.0%	\$151,326	\$128,183	18.1%
Diluted EPS	\$0.58	\$0.33	75.8%	\$1.70	\$1.43	18.9%

-----  
Add: One-Time Charge  
Related to Influenza  
Vaccine Contract (1)

Net Sales	-	-		-	-	
Operating Income	-	\$13,246		-	\$13,246	
Income from Continuing Operations	-	8,358		-	8,358	
Diluted EPS from Continuing Operations	-	0.10		-	0.10	
Net Income	-	8,358		-	8,358	
Diluted EPS	-	0.10		-	0.10	

Comparable Basis

Net Sales	\$1,343,141	\$1,156,122	16.2%	\$4,635,929	\$3,898,485	18.9%
Operating Income	\$89,235	\$63,491	40.5%	\$281,088	\$222,996	26.1%
Margin	6.6%	5.5%	115 bp	6.1%	5.7%	34 bp
Income from Continuing Operations	\$52,454	\$37,757	38.9%	\$162,388	\$133,694	21.5%
Diluted EPS from Continuing Operations	\$0.59	\$0.43	37.2%	\$1.82	\$1.50	21.3%
Net Income	\$51,700	\$37,908	36.4%	\$151,326	\$136,541	10.8%
Diluted EPS	\$0.58	\$0.43	34.9%	\$1.70	\$1.53	11.1%

(1) In the fourth quarter of 2004, there was a \$13.2 million pre-tax (\$8.4 million after tax) one-time charge associated with an agreement with Chiron Corporation to distribute Fluvirin influenza vaccine. This one-time charge was included in the "Selling, general and administrative" expense line on the statements of income.

Use of Non-GAAP Measures: The above information includes financial measures that are not calculated and presented in accordance with accounting principles generally accepted in the United States ("GAAP"). The above table reconciles operating income from continuing operations, net income and diluted earnings per share, the Company's most directly comparable measure calculated and presented in accordance with GAAP, to comparable amounts as adjusted to eliminate the effect of a one-time item.

Management eliminated the effect of such one-time item to assist in evaluating the underlying operational performance of the Company's

business, excluding such one-time item, over the periods presented. Management believes that this presentation is appropriate and facilitates such an evaluation by management, investors and analysts. This measure should be considered supplemental to, and not a substitute for or superior to, financial measures calculated in accordance with GAAP.

Note: Prior periods adjusted to reflect the effect of our discontinued operations.

Exhibit C

Henry Schein, Inc.  
Discontinued Operations 2005 Quarterly and Full Year Results  
(in thousands, except per share data)  
(unaudited)

					YTD
	Q1 2005	Q2 2005	Q3 2005	Q4 2005	Q4 2005
	-----	-----	-----	-----	-----
Sales	\$38,413	\$37,192	\$37,306	\$39,845	\$152,756
Income (loss) from discontinued operations (including write-down of long-lived assets of \$7.0 million, after tax)	\$407	\$(762)	\$(9,953)	\$(754)	\$(11,062)
Earnings (loss) from discontinued operations per share:					
Basic	\$0.00	\$0.00	\$(0.12)	\$(0.01)	\$(0.13)
Diluted	\$0.00	\$0.00	\$(0.12)	\$(0.01)	\$(0.12)

CONTACT: Henry Schein, Inc.  
Steven Paladino, 631-843-5500  
steven.paladino@henryschein.com  
OR  
Susan Vassallo, 631-843-5562  
susan.vassallo@henryschein.com

SOURCE: Henry Schein, Inc.